Newer intranasal migraine medications

American Family Physician

Volumn 61, Issue 1, 2000, Pages 180-186

  Logemann, Craig D ^a   Rankin, Lynn M ^b  

^a Iowa Lutheran Hospital   (United States)

^b Integra Health Medical Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; NARATRIPTAN; NOSE SPRAY; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; ZOLMITRIPTAN;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MIGRAINE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; CLINICAL TRIALS; DIHYDROERGOTAMINE; HALF-LIFE; HUMANS; INDOLES; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; PIPERIDINES; RECURRENCE; SEROTONIN AGONISTS; SUMATRIPTAN; TRIAZOLES; TRYPTAMINES;

EID: 0033963382     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9.
2. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43(6 suppl 3):S6-10.
3. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35:387-96.
4. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21
5. Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993;43:1363-8 [Published erratum in Neurology 1993;43:2010].
6. Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995;25:464-9 [Published erratum in Ann Emerg Med 1995;25:857].
7. Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 1991;11:129-34.
8. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984;4:107-11.
9. Volans GN. Migraine and drug absorption. Clin Pharmacokinet 1978;3:313-8.
10. Volans GN. Absorption of effervescent aspirin during migraine. Br Med J 1974;4:265-8.
11. Package Insert. Dihydroergotamine mesylate nasal spray (Migranal). East Hanover, N.J.: Novartis Pharmaceuticals Co., 1997.
12. Package Insert. Sumatriptan Nasal Spray (Imitrex). Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1997.
13. Package insert. Sumatriptan succinate tablets (Imitrex). Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1998.
14. Package insert. Sumatriptan succinate injection (Imitrex). Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1997.
15. Package insert. Naratriptan hydrochloride (Amerge) tablets. Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1998.
16. Package insert. Rizatriptan (Maxalt) tablets. West Point, Pa: Merck & Co., Inc., 1998.
17. Package insert. Zolmitriptan (Zomig) tablets. Wilmington, Delaware: Zeneca Pharmaceutical, 1997.
18. Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44(3 pt 1):447-53.
19. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neural 1996;53:1285-91.
20. The Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995;35:177-84.
21. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 1997;49:1225-30.
22. Diamond S, Elkind A, Jackson RT Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 1998;7:234-40.
23. Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrence. Cephalagia 1994; 14:330-8.
24. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. The Naratriptan S2WA3001 Study Group. Headache 1997;37:640-5.
25. Matthew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 1997;49:1485-90.
26. Rapoport AM, Ramadan NM, Adelman JU, Matthew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997;49:1210-8.
27. Moore KL, Noble SL. Drug treatment of migraine: Part I. Acute therapy and drug-rebound headache. Am Fam Physician 1997;56:2039-48,2051-4.
28. Schweitzer SO. The economics of migraine (Presentation). Am J Manag Care 1999;5(2 suppl):S91-8.